Dana-Farber Cancer Institute | Strategic Alliance Partners

Matthew S. Davids, MD, MMSc, discusses investigational doublets and triplets in chronic lymphocytic leukemia.

Matthew S. Davids, MD, MMSc, discusses the shift away from chemoimmunotherapy in chronic lymphocytic leukemia and ongoing research in the space.

Matthew S. Davids, MD, MMSc, discusses selecting between continuous and time-limited therapy in chronic lymphocytic leukemia.

Ziad Bakouny, MD, MSc, discusses the rate of disease progression in sarcomatoid carcinoma.

Matthew S. Davids, MD, MMSc, discusses factors to consider when selecting treatment for patients with chronic lymphocytic leukemia.

Nancy U. Lin, MD, discusses the challenges faced in the treatment of patients with HER2-positive breast cancer and brain metastases.

Toni Choueiri, MD, discusses the CheckMate-9ER trial, the next steps for nivolumab/cabozantinib, and other cabozantinib regimens under exploration.

The combination of nivolumab plus chemotherapy resulted in a statistically significant improvement in pathologic complete response when used as neoadjuvant treatment in patients with resectable non–small cell lung cancer, meeting the primary end point of the phase 3 CheckMate-816 trial.

Matthew S. Davids, MD, MMSc, discusses the use of chemoimmunotherapy in patients with chronic lymphocytic leukemia.

Dana-Farber Cancer Institute has launched the Center for Salivary and Rare Head and Neck Cancers to treat patients with rare and occasionally aggressive cancers arising from the head and neck.

Sara M. Tolaney, MD, MPH, discusses the phase 2 APT and ATEMPT trials in stage I HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, discusses the evolution of treatment in HER2-positive breast cancer.

Paul L. Nguyen, MD, discusses treatment considerations in high-risk prostate cancer.

Atish D. Choudhury, MD, PhD, discusses the design of key clinical trials in nonmetastatic castration-resistant prostate cancer.

Although frontline chemoimmunotherapy regimens have been the gold standard for patients with chronic lymphocytic leukemia for many years, the advent of BTK inhibitors and other novel drugs has moved the field toward adopting chemotherapy-free options for patients in this setting.

Paul L. Nguyen, MD, discusses standard and investigational treatment options in high-risk prostate cancer.

In our exclusive interview, Jacob Sands, MD, discusses the FDA approval of lurbinectedin in small cell lung cancer and shed light on key findings from the phase 2 basket trial that served as the basis for the approval.

Paul L. Nguyen, MD, discusses the optimal duration of androgen deprivation therapy in patients with high-risk prostate cancer.

Atish D. Choudhury, MD, PhD, discusses the goal of treating patients with nonmetastatic castration-resistant prostate cancer.

Atish D. Choudhury, MD, PhD, compares the safety profiles of antiandrogen agents in nonmetastatic castration-resistant prostate cancer.

Quoc-Dien Trinh, MD, discusses the challenges of re-establishing standard surgical procedures in patients with prostate cancer following the initial wave of the coronavirus disease 2019 pandemic.

Quoc-Dien Trinh, MD, discusses the impact of the coronavirus disease 2019 pandemic on prostate cancer.

Atish D. Choudhury, MD, PhD, discusses the different states of nonmetastatic castration-resistant prostate cancer.

Quoc-Dien Trinh, MD, discusses current strategies on the treatment of patients with high-risk prostate cancer during the COVID-19 crisis.

David P. Steensma, MD, discusses the importance of evaluating eprenetapopt in the pivotal phase 3 study, the agent’s potential role in the MDS landscape, and some of the questions that remain in this setting.

Paul L. Nguyen, MD, discusses the utility of adding a brachytherapy boost to radiation therapy in the ASCENDE-RT trial.

Bradley McGregor, MD, discusses future research in metastatic castration-resistant prostate cancer.

Atish D. Choudhury, MD, PhD, discusses clinical trials of interest examining different agents, such as darolutamide, enzalutamide, and apalutamide in patients with nonmetastatic castration-resistant prostate cancer.

In our exclusive interview, Sara M. Tolaney, MD, MPH, shares insight on how risk status is being used to tailor HER2-directed therapies to patients with early-stage HER2-positive breast cancer, key trials focused on delineating optimal deescalated and escalated treatment strategies, and ongoing research in the HER2-low setting.

Atish D. Choudhury, MD, PhD, discusses antiandrogen treatment selection in nonmetastatic castration-resistant prostate cancer.